Neuro-co-cardiological DiseasesNCT07012668
Outcomes and Risk Factors of Different Treatment Strategies for Neuro-co-cardiological Diseases and Post-cardiac Surgery Cerebrovascular Diseases
An observational study of Neuro-co-cardiological Diseases and Post-cardiac Surgery Cerebrovascular Diseases, run by Beijing Anzhen Hospital at 1 site in China.
Trial summary
The objective of this observational cohort study is to evaluate the clinical outcomes of various treatment strategies for cerebrovascular and cardiovascular diseases. Furthermore, it aims to investigate the factors that influence adverse outcomes from these treatments. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Neuro-co-cardiological Diseases, Post-cardiac Surgery Cerebrovascular Diseases, Vascular Lesion
- What is being tested?
- Interventional or surgical treatment
- Type of treatment
- Surgery or procedure
- How many people
- 2,000 participants
- Where
- 1 siteChina
- Study dates
- 19 Sep 2024to 19 Sep 2027
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with neuro-co-cardiological diseases or post-cardiac surgery cerebrovascular diseases
Who may be able to join
- Age ≥18 years;
- Patients with neuro-co-cardiological diseases or post-cardiac surgery cerebrovascular diseases.
Who cannot join
- The expected survival is less than 1 years;
- Simultaneously merge other serious diseases;
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Beijing Anzhen Hospital
Beijing
Xin Tong, M.D., 17810651085 ext. 86, Tomice123@foxmail.com
About this study
The objective of this observational cohort study is to evaluate the clinical outcomes of various treatment strategies for cerebrovascular and cardiovascular diseases. Furthermore, it aims to investigate the factors that influence adverse outcomes from these treatments.
- Conditions
- Neuro-co-cardiological Diseases, Post-cardiac Surgery Cerebrovascular Diseases, Vascular Lesion
- Being tested
- Interventional or surgical treatment
- Keywords
- Neuro-co-cardiological diseases, Post-cardiac surgery Cerebrovascular diseases, Simultaneous treatment, Staged treatment, Conservative treatment
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Interventional or surgical treatmentProcedure or surgery
Simultaneous interventional or surgical treatment/staged interventional or surgical treatment
Interventional or surgical treatmentProcedure or surgery
Interventional or surgical treatment
| Study group | Role | What they receive |
|---|---|---|
| Neuro-co-cardiological diseases: Simultaneous treatment | Simultaneous interventional therapy/Simultaneous surgical treatment/ Simultaneous hybrid surgical treatment Receives: Procedure: Interventional or surgical treatment | |
| Neuro-co-cardiological diseases: Staged treatment | Staged interventional therapy/Staged surgical treatment/Staged hybrid surgical treatment Receives: Procedure: Interventional or surgical treatment | |
| Neuro-co-cardiological diseases: Conservative treatment | Surgery/intervention for one disease and conservative treatment for another disease or Simultaneously conservative treatment | |
| Post-cardiac surgery Cerebrovascular disease: Surgery/Interventional Treatment | Post-cardiac surgery Cerebrovascular disease: Surgery/Interventional Treatment Receives: Procedure: Interventional or surgical treatment | |
| Post-cardiac surgery Cerebrovascular disease: Conservative treatment | Post-cardiac surgery Cerebrovascular disease: Conservative treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Modified Rankin Scale Score
Modified Rankin Scale（0-6）, A lower MRS score indicates better functional status for the patient.
Measured: 90±7 days
Secondary outcomes (7)
Modified Rankin Scale Score
Modified Rankin Scale（0-6）, A lower MRS score indicates better functional status for the patient.
Measured: 7±1 days or the day discharged
Modified Rankin Scale Score
Modified Rankin Scale（0-6）, A lower MRS score indicates better functional status for the patient.
Measured: 365±30 days
Perioperative complication rate
Measured: 30±7 days
Rate of cardiovascular and cerebrovascular events
Measured: 90±7 days
Rate of cardiovascular and cerebrovascular events
Measured: 365±30 days
Short-term complications
Measured: 90±7 days
Long-term complications
Measured: 365±30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2025
- Study start19 Sep 2024
- Primary completion19 Sep 2027 (estimated)
- Study completion19 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neuro-co-cardiological DiseasesStudies of the same condition, open and under way.
- More trials run by Beijing Anzhen HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 2,000 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Beijing Anzhen Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xiaochuan Huo, Beijing Anzhen Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07012668
- Sponsor's protocol ID
- ANGEL-NEUROCARD
- Status last verified
- Jun 2025
- First submitted
- 1 Jun 2025
- Last updated
- 12 Jun 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Outcomes and Risk Factors of Different Treatment Strategies for Neuro-co-cardiological Diseases and Post-cardiac Surgery Cerebrovascular Diseases
- ClinicalTrials.gov ID
- NCT07012668
- Acronym / sponsor ID
- ANGEL-NEUROCARD
- Conditions
- Neuro-co-cardiological Diseases, Post-cardiac Surgery Cerebrovascular Diseases, Vascular Lesion
- Keywords
- Neuro-co-cardiological diseases, Post-cardiac surgery Cerebrovascular diseases, Simultaneous treatment, Staged treatment, Conservative treatment
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Beijing Anzhen HospitalUniversity, hospital or other
- Study start
- 19 Sep 2024 (actual)
- Primary completion
- 19 Sep 2027 (estimated)
- Study completion
- 19 Sep 2027 (estimated)
- First posted
- 10 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this observational cohort study is to evaluate the clinical outcomes of various treatment strategies for cerebrovascular and cardiovascular diseases. Furthermore, it aims to investigate the factors that influence adverse outcomes from these treatments.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 1 Year
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Neuro-co-cardiological diseases: Simultaneous treatment | – | Procedure: Interventional or surgical treatmentSimultaneous interventional therapy/Simultaneous surgical treatment/ Simultaneous hybrid surgical treatment |
| Neuro-co-cardiological diseases: Staged treatment | – | Procedure: Interventional or surgical treatmentStaged interventional therapy/Staged surgical treatment/Staged hybrid surgical treatment |
| Neuro-co-cardiological diseases: Conservative treatment | – | –Surgery/intervention for one disease and conservative treatment for another disease or Simultaneously conservative treatment |
| Post-cardiac surgery Cerebrovascular disease: Surgery/Interventional Treatment | – | Procedure: Interventional or surgical treatmentPost-cardiac surgery Cerebrovascular disease: Surgery/Interventional Treatment |
| Post-cardiac surgery Cerebrovascular disease: Conservative treatment | – | –Post-cardiac surgery Cerebrovascular disease: Conservative treatment |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with neuro-co-cardiological diseases or post-cardiac surgery cerebrovascular diseases
Key inclusion criteria (2 listed)
- Age ≥18 years;
- Patients with neuro-co-cardiological diseases or post-cardiac surgery cerebrovascular diseases.
Key exclusion criteria (2 listed)
- The expected survival is less than 1 years;
- Simultaneously merge other serious diseases;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Interventional or surgical treatmentSimultaneous interventional or surgical treatment/staged interventional or surgical treatment | Procedure or surgery | Neuro-co-cardiological diseases: Simultaneous treatment, Neuro-co-cardiological diseases: Staged treatment |
| Interventional or surgical treatmentInterventional or surgical treatment | Procedure or surgery | Post-cardiac surgery Cerebrovascular disease: Surgery/Interventional Treatment |
Primary outcome
Modified Rankin Scale Score
Time frame: 90±7 days
Modified Rankin Scale（0-6）, A lower MRS score indicates better functional status for the patient.
7 secondary outcomes
Modified Rankin Scale Score
Time frame: 7±1 days or the day discharged
Modified Rankin Scale Score
Time frame: 365±30 days
Perioperative complication rate
Time frame: 30±7 days
Rate of cardiovascular and cerebrovascular events
Time frame: 90±7 days
Rate of cardiovascular and cerebrovascular events
Time frame: 365±30 days
Short-term complications
Time frame: 90±7 days
Long-term complications
Time frame: 365±30 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2025.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neuro-co-cardiological Diseases and Post-cardiac Surgery Cerebrovascular Diseases, run by Beijing Anzhen Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xiaochuan Huo, M.D. (+86 13716292262, huoxiaochuan@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Modified Rankin Scale Score (time frame: 90±7 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2025.